Are there sex-related differences in the number of circulating endothelial microparticles (EMPs) and microparticle microRNA expression in middle-aged adult humans? r What is the main finding and its importance?
Introduction
Cardiovascular disease (CVD) is the leading cause of death in the USA (Benjamin et al. 2017) . Between the ages of 45 and 65 years, men have three times greater CVD risk compared with women, despite marginal sex-associated differences in traditional cardiovascular risk factors (Perelshtein Brezinov et al. 2016) . To date, the mechanisms responsible for this sex-related difference in CVD risk and events are not well understood, resulting in substantial clinical and public health challenges.
Endothelial microparticles (EMPs; 0.1-1.0 μm in size) are shed from endothelial cells as a result of cellular activation or apoptosis (Shai & Varon, 2011) . Recently, EMPs have emerged as prognostic and diagnostic markers of CVD because of their role in the initiation, development and progression of atherosclerosis (Burger et al. 2011) . Elevations in the circulating number of EMPs have been observed in a number of vascular pathologies, such as coronary artery disease, ischaemic stroke and diabetes (Werner et al. 2006) . Moreover, EMPs have been shown to contribute directly to atherogenesis by inducing endothelial activation, inflammation and dysfunction (Esposito et al. 2006; Abid Hussein et al. 2008; Curtis et al. 2009 ). Endothelial microparticles are also known to carry and transfer microRNAs (miRNA or miR) to target tissues, including endothelial cells (Bernardo et al. 2016) . miRNAs are ß22 nt non-coding RNAs involved in the regulation of a number of physiological and pathophysiological processes. Altered expression of vascular-related miRNAs, specifically miR-34a, miR-92a, miR-125a and miR-126, within EMPs has been linked with adverse vascular outcomes (Jansen et al. 2013; Bernardo et al. 2016) . For example, in vitro and in vivo studies have demonstrated that lower EMP expression of miR-126 is associated with greater atherosclerotic plaque burden in mice and a higher incidence of atherosclerotic vascular disease in middle-aged adults (Jansen et al. 2013 (Jansen et al. , 2014 . Currently, it is unknown whether there are sex-related differences in circulating EMPs and their miRNA cargo in healthy, middle-aged adults.
Accordingly, the experimental aims of this study were to determine: (i) whether circulating concentrations of EMPs differ in middle-aged women compared with men; and (ii) whether there are sex-related differences in miRNA expression in circulating EMPs. Endothelial microparticles and their miRNA content might provide new insight into sex-related discrepancy in CVD risk in middle-aged adults.
Methods
Ethical approval. The ethical committee of the University of Colorado Boulder approved the study (approval no. 0304.25). The study conformed to the standards set by the Declaration of Helsinki. Before participation, all subjects had the research study and its potential risks and benefits explained fully before providing written informed consent according to the guidelines of the University of Colorado at Boulder.
Subjects. Peripheral blood samples were collected from 30 healthy, sedentary middle-aged adults (age range 45-65 years): 15 men and 15 women. All subjects were non-obese (body mass index ࣘ30 kg m −2 ), normotensive, non-smokers, normolipidaemic, non-medicated and free of overt cardiovascular, renal, metabolic and haematological diseases as assessed by medical history, resting and exercise ECGs and fasting blood chemistry. All women were at least 1 year postmenopausal (mean 5.3 ± 1.4 yr) and had never taken or had discontinued use of hormone replacement therapy at least 2 years before the start of the study.
Body composition and metabolic measures. Body mass was measured to the nearest 0.1 kg using a medical beam balance. Body mass index and minimal waist circumference were measured according to published guidelines (Lohman et al. 1988) . Fasting plasma lipid, lipoprotein, glucose and insulin concentrations were determined using standard techniques.
Circulating microparticles. Venous blood from an antecubital vein was collected into tubes containing sodium citrate and centrifuged at 1500g for 10 min at room temperature. Plasma was collected and stored at −80°C for batch analysis. For the characterization and quantification of circulating EMP subspecies, all plasma samples were centrifuged at 13,000g for 2 min, and 200 μl was transferred to a TruCount tube (BD Biosciences, Franklin Lakes, NJ, USA). The EMP phenotype was determined using markers indicative of activation (CD62e) and apoptosis (CD31/CD42b; BioLegend, San Diego, CA, USA). Samples were incubated with the flourochrome-labelled antibodies for 20 min in the dark at room temperature. After incubation, samples were fixed with 2% paraformaldehyde (ChemCruz Biochemicals, Santa Cruz, CA, USA) and diluted with RNase-free PBS. The microparticle size threshold was established using Megamix-Plus SSC calibrator beads (Megamix-Plus SSC beads; Biocytex, Marseille, France), and only events <1 μm in size and positively expressing markers of activation (CD62e + ) and apoptosis (CD31 + /CD42b − ) were counted and sorted by flow cytometry (BD Biosciences FACSAria I; Nielsen et al. 2014) . A total of 25,000 activation-and apoptosis-derived EMPs were sorted directly into RNase-free Eppendorf microtubes containing 250 μl of RNase-free PBS. The concentrations of activation-and apoptosis-derived EMPs were determined using the following formula: [(number Microparticle miRNA. Total RNA was isolated from sorted activation-and apoptosis-derived EMPs using the miRNeasy FFPE Kit (Qiagen, Hilden, Germany; Arzt et al. 2011). Samples were centrifuged at 21,000g for 30 min at 4°C to pellet EMPs. The supernatant was removed, and RNA was extracted from pelleted EMPs, treated with 1/10 v/v DNase 1 for 15 min to remove genomic or cell-free DNA, immobilized, washed and eluted in 18.5 μl of RNAse-free water (Arzt et al. 2011) . To normalize for RNA content between samples, 3.5 μl (1.6 × 10 8 copies μl −1 ) of Canorhabditis elegans miR-39 (cel-miR-39) was added during the RNA isolation. Immediately after isolation, 12 μl of total RNA was reverse transcribed using the miScript Reverse Transcription Kit (Qiagen; Hao et al. 2014) . Complementary DNA was PCR amplified on the CFX96 (BioRad) RT-PCR platform using the miScript SYBR green PCR kit and miRNA-specific primers (Qiagen; Hao et al. 2014) . All samples were assayed in duplicate. Relative expression (RE) per EMP for a given miRNA was normalized to cel-miR-39, calculated as ] /EMP and expressed as arbitrary units (a.u.; Hao et al. 2014 ).
Statistical analysis. Group differences in subject characteristics, circulating numbers of activation-and apoptosis-derived EMPs and EMP miRNA expression were determined by ANOVA. Data are reported as means ± SD. Statistical significance was set a priori at P < 0.05.
Results
Selected subject characteristics are presented in Table 1 . Although none of the subjects was obese, the men demonstrated significantly higher body mass and waist circumference and lower percentage body fat compared with the women. Other than high-density lipoprotein cholesterol, there were no significant differences in metabolic or haematological variables between the groups.
There were no sex-related differences in circulating concentrations of activation-and apoptosis-derived EMPs. Concentrations of circulating activation-(33 ± 31 versus 39 ± 35 microparticles μl −1 ) and apoptosis-derived EMPs (49 ± 54 versus 42 ± 43 microparticles μl −1 ) were similar between the men and women (Fig. 1) . The EMP miRNA expression signature between the activated-and apoptosis-derived EMPs was not significantly different within each group; however, differential expression of specific miRNAs in each subspecies was observed between the groups. In activation-derived EMPs, there were no significant differences in the expression of miR-34a (0.36 ± 0.9 versus 0.41 ± 0.09 a.u.), miR-92a (2.63 ± 3.33 versus 3.49 ± 3.72 a.u.) and miR-126 (1.32 ± 1.12 versus 1.55 ± 1.35 a.u.) in men compared with women; however, miR-125a expression was markedly lower (ß215%; P < 0.05) in activation-derived EMPs from men (2.23 ± 2.01 a.u.) compared with women (6.95 ± 3.99 a.u.; Fig. 2 ). With respect to apoptosis-derived EMPs, there were no significant sex-related differences in the expression of miR-92a (4.31 ± 4.06 versus 3.66 ± 2.67 a.u.), miR-125a (5.36 ± 6.93 versus 6.94 ± 9.14 a.u.) or miR-126 (1.32 ± 1.39 versus 1.23 ± 0.97 a.u.). Expression of miR-34a, however, was significantly higher (ß210%) in circulating apoptosis-derived EMPs from men (1.17 ± 1.43 a.u.) compared with women (0.38 ± 0.35 a.u.; Fig. 2 ).
In the overall study population, EMP expression of miR-125a was modestly, albeit significantly, associated with percentage body fat and high-density lipoprotein (HDL)-cholesterol. Expression of miR-125a in activation-derived EMPs was positively associated with percentage body fat (r = 0.41) and HDL-cholesterol (r = 0.49).
Discussion
Clinical interest in circulating EMPs has intensified because of their pathological role in atherosclerotic vascular disease (Sinning et al. 2011) and their value as a vascular biomarker of disease risk and severity (Werner et al. 2006) . Indeed, higher circulating EMP concentrations are significantly associated with increased CVD risk and events (Amabile et al. 2009 ). The new findings of the present study are as follows: (i) circulating concentrations of EMPs are not significantly different in healthy, middle-aged women and men; however, (ii) there are sex-related differences in the expression of miR-125a and miR-34a contained in activationand apoptosis-derived EMPs, respectively. Differential expression of these vascular-related miRNAs has been linked to endothelial dysfunction and CVD risk (Hao et al. 2014; Bernardo et al. 2016) . Given their potential role in regulating target cell function and their link to vascular disease , circulating EMP miRNA content might contribute to the disparate CVD rates between middle-aged women and men.
Elevations in circulating EMPs are not only considered to be a consequence and biomarker of endothelial activation, injury and apoptosis but also causative agents in vascular damage, dysfunction and disease (Burger et al. 2012) . In addition, there is increasing evidence supporting their strong predictive and prognostic value with CVD risk, events and outcome (Amabile et al. 2009) . It is now recognized that endothelial cells release phenotypically and quantitatively distinct EMPs in response to cell activation or apoptosis (Jimenez et al. 2003) . Thus, circulating concentrations of activation-derived (CD62e + microparticles) and apoptosis-derived EMPs (CD31 + /CD42b − microparticles) are considered to provide a sensitive index of endothelial health and, in turn, cardiovascular risk (Curtis et al. 2013) . Elevations in both subspecies of EMPs have been linked to greater vascular risk and disease burden by promoting and generating a pro-inflammatory environment and by supporting coagulation and thrombosis (Sabatier et al. 2002) . Given the potential role of EMPs in disease pathology, it was somewhat surprising that we observed 
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no sex-related difference in circulating concentrations of either activation-or apoptosis-derived EMPs in the present study. Levels of both species of EMPs were almost identical between the groups of middle-aged women and men. Interestingly, Toth et al. (2007) reported significantly higher circulating concentrations of activation-derived EMPs in premenopausal women compared with men of similar age. Moreover, the sex-related difference in activated EMPs was most apparent during the luteal phase of the menstrual cycle, suggesting menstrual cycle-related influences on EMP release. All of the women in the present study were postmenopausal. The absence of menstrual cycle-induced disturbances of the endothelium (Rank et al. 2012 ) might account for the lack of higher circulating EMPs in our middle-aged women.
In the present study, we focused on a specific subset of vascular-related miRNAs: miR-34a, miR-92a, miR-125a and miR-126. Altered expression of these miRNAs has been implicated in key features of the atherosclerotic disease process, such as endothelial cell senescence and apoptosis (miR-34a), inflammation (miR-92a and miR-126) and vascular vasomotor regulation (miR-125a; Li et al. 2010; Zhao et al. 2010; Fang & Davies, 2012; Feinberg & Moore, 2016) . Moreover, recent studies indicate that miRNAs carried by EMPs are more biologically active and predictive of atherosclerotic disease compared with freely circulating miRNAs in plasma (Jansen et al. 2014) . For example, Jansen et al. (2013) reported that the miRNA signature in circulating EMPs could directly affect the vascular endothelium, promoting a pro-atherogenic endothelial phenotype. In addition, miRNA expression in EMPs has been shown to be independently predictive of adverse cardiac events in patients with coronary artery disease (Jansen et al. 2014) . In the present study, we observed sex-related differential expression of miRNAs in activation-and apoptosis-derived EMPs. To our knowledge, this is the first study to determine the influence of sex on miRNAs contained in circulating EMPs. In circulating activation-derived EMPs, expression of miR-125a was markedly lower (ß215%) in microparticles from men than women. Lower expression of miR-125a has been linked to endothelial dysfunction and atherosclerosis (Hao et al. 2014) . Interestingly, miR-125a is an important negative regulator of the vasoconstrictor peptide endothelin-1 . It is plausible that lower EMP miR-125a expression might contribute to the greater endothelium-mediated endothelin-1 vasoconstrictor tone reported in middle-aged men compared with women (Stauffer et al. 2010) . In circulating apoptosis-derived EMPs, expression of miR-34a was substantially higher (ß210%) in the microparticles from the men compared with the women. miR-34a has been shown to influence endothelial cell senescence and apoptosis (Yamakuchi et al. 2008) . Zhou et al. (2014) eloquently demonstrated in vivo that microparticle transfer of miR-34a enhances cellular apoptosis by altering the expression of the anti-apoptotic molecule Bcl-2. Endothelial cell senescence and apoptosis are fundamental features in the atherosclerotic process (Yamakuchi et al. 2008) ; it is plausible that sex-related differences in EMP miR-34a content might influence the senescent and apoptotic propensity of the endothelium and, in turn, atherogenic consequences. To address this intriguing postulate, we are currently determining whether EMPs from middle-aged men induce a more pro-atherogenic endothelial phenotype, specifically a phenotype more susceptible to senescence and apoptosis.
There are a few experimental considerations that deserve mention. Firstly, given our cross-sectional study design, we cannot dismiss the possibility that genetic and/or lifestyle factors might have influenced our results. However, it is important to emphasize that although a number of pathological, pharmacological and physiological factors can influence the number of EMPs and the miRNA content (Werner et al. 2006; Amabile et al. 2009; Burger et al. 2011) , all of the adults in the present study were free of overt disease, non-medicated, non-smokers and sedentary, thus minimizing the potential influence of lifestyle behaviours and underlying pathology on our results. In addition, all women were postmenopausal and not taking hormone replacement therapy, thus negating the possible confounding hormone-mediated effects, such as those of oestrogen, on the number of EMPs and miRNA expression. Secondly, the subset of miRNAs assessed in the present study is certainly not inclusive of all vascular-related miRNAs (Qin & Zhang, 2011) . As such, the results of the present study must be viewed within the context of the specific miRNAs presented. We focused on the present miRNA signature because these miRNAs are enriched in endothelial cells (Sun et al. 2013 ) and play putative roles in endovascular disease Wu et al. 2011; Jansen et al. 2014) . Owing to their expression in endothelial cells, they represented logical targets for determining the miRNA cargo in endothelium-derived microparticles. Lastly, the present study was not designed to address the mechanisms underlying possible EMP classification-or sex-related differences in microparticle miRNA packaging. Although we observed significant relations between the expression miR-125a in activation-derived EMPs and the percentage body fat and HDL-cholesterol, the physiological relevance of these correlations is not clear. In addition to the sex-related differences in EMP miRNA expression reported herein, it is interesting to note that the miRNA contents in both activation-and apoptosis-derived EMPs were similar. Indeed, independent of sex, the amounts of miR-34a, miR-92a, miR-125a and miR-126 contained in the EMPs were not significantly different across subspecies. Future studies are needed to determine whether the vascular effects of EMPs are more dependent upon their source of origin or their miRNA content.
In conclusion, the results of the present study demonstrate that although circulating numbers of EMPs (both activation-and apoptosis-derived EMPs) do not differ between middle-aged men and women, microRNA expression in circulating EMPs appears to be distinctly influenced by sex. Sex-related differences in EMP microRNA cargo may significantly influence how EMPs affect the function of various target tissues, especially endothelial cells, and, in turn, influence vascular risk.
